Novo Nordisk
NVO
$123.05
Share price
-0.78%
Change (1 day)
47.19%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Novo Nordisk (NVO) - P/B ratio
P/B ratio as of May 2024 : 35.2
According to Novo Nordisk's latest financial reports the company has a price-to-book ratio of 35.2.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Novo Nordisk - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 29.2 | 15.38% |
| 2022-12-31 | 25.3 | 6.95% |
| 2021-12-31 | 23.7 | 52.01% |
| 2020-12-31 | 15.6 | -3.3% |
| 2019-12-31 | 16.1 | 14.45% |
| 2018-12-31 | 14.1 | -13.79% |
| 2017-12-31 | 16.3 | 11.13% |
| 2016-12-31 | 14.7 | -33.6% |
| 2015-12-31 | 22.1 | 29.3% |
| 2014-12-31 | 17.1 | 33.29% |
| 2013-12-31 | 12.8 | 1.69% |
| 2012-12-31 | 12.6 | 23.48% |
| 2011-12-31 | 10.2 | -0.13% |
| 2010-12-31 | 10.2 | 74.1% |
| 2009-12-31 | 5.88 | 12.05% |
| 2008-12-31 | 5.25 | -21.13% |
| 2007-12-31 | 6.65 | 33.99% |
| 2006-12-31 | 4.97 | 19.09% |
| 2005-12-31 | 4.17 | 12.43% |
| 2004-12-31 | 3.71 | 12.2% |
| 2003-12-31 | 3.31 | 8.01% |
| 2002-12-31 | 3.06 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.76 | -95.01% | 🇺🇸 USA |
 Eli Lilly LLY | 66.1 | 87.95% | 🇺🇸 USA |
 Sanofi SNY | 1.50 | -95.73% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 5.35 | -84.79% | 🇺🇸 USA |